Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.
Large B-cell Lymphoma
DRUG: Tafasitamab|DRUG: Lenalidomide
Complete Response Rate (CRR), Complete Response Rate (CRR) is defined as the proportion of patients with a Complete Response (CR), Up to 3 months
Objectives Response Rate (ORR), Defined as the incidence of either a complete response (CR) or a partial response (PR) per Lugano Classification as determined by study investigators., Up to 12 months|Duration of Response (DoR), DoR is defined as the date of their first objective response to disease progression per Lugano Classification as determined by study investigators or death from any cause., Up to 12 months|Progression Free Survival (PFS), Defined as the time from tafasitamab infusion date to the date of disease progression per Lugano Classification as determined by study investigators or death from any cause., Up to 12 months
The purpose of the study is to evaluate the safety and efficacy of tafasitamab and lenalidomide in participants with Large B Cell Lymphoma (LBCL) after axicabtagene ciloleucel (axi-cel) treatment. Participants will be asked to spend about 12 months in this study.